sellModerate cluster of 9
Shamim Ruff sold $481k of RETA
director at REATA PHARMACEUTICALS INC. 5,740 shares at an average of $83.73, traded Mar 10, 2023, filed Mar 13, 2023.
Warning score
53Value
$481k
5,740 shares
Holdings after
5,223
-52% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +18Trade size$481k at market
- +20Share of holdings soldSold 52% of holdings
- +15Cluster9 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001209191-23-018231, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 10, 2023 | MOption exercise Class A common stock | +199 | $27.32 | $5,437 | 5,422 | Mar 13, 2023 |
| Mar 10, 2023 | MOption exercise Class A common stock | +1,326 | $34.76 | $46k | 6,748 | Mar 13, 2023 |
| Mar 10, 2023 | MOption exercise Class A common stock | +4,215 | $34.76 | $147k | 10,963 | Mar 13, 2023 |
| Mar 10, 2023 | SOpen-market sale Class A common stock | -5,740 | $83.73 | $481k | 5,223 | Mar 13, 2023 |
| Mar 10, 2023 | MOption exercise Stock Option (right to buy)derivative | -199 | $0.00 | $0 | 0 | Mar 13, 2023 |
| Mar 10, 2023 | MOption exercise Stock Option (right-to-buy)derivative | -1,326 | $0.00 | $0 | 443 | Mar 13, 2023 |
| Mar 10, 2023 | MOption exercise Stock Option (right-to-buy)derivative | -4,215 | $0.00 | $0 | 1,405 | Mar 13, 2023 |
Related signals
Other insiders at REATA PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 57Moderate | REATA PHARMACEUTICALS INC | Dawn Carter Bir Chief Commercial Officer | $808k 9,317 shares | -22% | |
| 50Moderate | REATA PHARMACEUTICALS INC | Andrea Loewen SVP, Global Regulatory Affairs | $1.6M 19,036 shares | -33% | |
| 30Weak | REATA PHARMACEUTICALS INC | Bhaskar Anand SVP, Chief Accounting Officer | $14k 165 shares | -1% | |
| 60Notable | REATA PHARMACEUTICALS INC | Dawn Carter Bir Chief Commercial Officer | $8.5M 96,996 shares | -100% | |
| 45Moderate | REATA PHARMACEUTICALS INC | Samina Khan SVP, Chief Medical Officer | $331k 3,961 shares | -9% | |
| 37Weak | REATA PHARMACEUTICALS INC | Colin John Meyer Chief Innovation Officer | $53k 621 shares | -1% | |
| 36Weak | REATA PHARMACEUTICALS INC | Michael D Wortley Chief Legal Officer | $35k 414 shares | -1% | |
| 44Moderate | REATA PHARMACEUTICALS INC | Manmeet Singh Soni COO, CFO and President | $53k 622 shares | -1% | |
| 38Weak | REATA PHARMACEUTICALS INC | Bhaskar Anand SVP, Chief Accounting Officer | $72k 820 shares | -3% | |
| 42Moderate | REATA PHARMACEUTICALS INC | Dawn Carter Bir Chief Commercial Officer | $191k 2,166 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.